CHOP Hematologist Dr. Lindsey George Receives 2019 Clinical Achievement Research Award
Published on in CHOP News
Dr. George was recognized for the first gene therapy clinical trial to report a cure of hemophilia B patients.
Published on in CHOP News
Dr. George was recognized for the first gene therapy clinical trial to report a cure of hemophilia B patients.
Published on in CHOP News
CHOP breakthrough helps scientists edge closer to defeating a longtime enemy of human health: hemophilia, the inability to form blood clots.
Published on in CHOP News
A team of gene therapy researchers has reported on a highly active gene variant that achieved sustained factor levels in 10 adults, with no adverse effects.
Published on in CHOP News
A clinical trial of a gene therapy for hemophilia B is allowing patients to avoid painful, disabling internal bleeds.
Published on in CHOP News, International Update
In a clinical trial led by a CHOP researcher, adult patients with hemophilia B were able to pursue daily activities without disabling bleeds.
Published on in CHOP News
CHOP’s Katherine High, MD, was honored for her trailblazing research in the bleeding disorder hemophilia with a national award from the American Society of Hematology.
Published on in CHOP News
Gene therapy researchers from The Children's Hospital of Philadelphia created a decoy to fool the immune system, preventing it from mistakenly defeating the benefits delivered by a corrective gene.
Published on in Beyond Blood
Genetic testing can help us better estimate risk for inhibitor formation, since inhibitors are more common with certain mutations causing hemophilia.
Published on in Beyond Blood
Children and adolescents with bleeding and clotting disorders (who may be on anticoagulation therapy), picking a sport requires special consideration to minimize risks of bleeding.
Published on in Beyond Blood
In December 2012, CHOP opened a gene therapy clinical trial for patients older than 18 years of age, with factor IX levels equal to or less than 2 percent.